Literature DB >> 21697467

Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site.

Kabamba Bankoledi Alexandre1, Elin S Gray, Ralph Pantophlet, Penny L Moore, James B McMahon, Ereck Chakauya, Barry R O'Keefe, Rachel Chikwamba, Lynn Morris.   

Abstract

The glycans on HIV-1 gp120 play an important role in shielding neutralization-sensitive epitopes from antibody recognition. They also serve as targets for lectins that bind mannose-rich glycans. In this study, we investigated the interaction of the lectin griffithsin (GRFT) with HIV-1 gp120 and its effects on exposure of the CD4-binding site (CD4bs). We found that GRFT enhanced the binding of HIV-1 to plates coated with anti-CD4bs antibodies b12 and b6 or the CD4 receptor mimetic CD4-IgG2. The average enhancement of b12 or b6 binding was higher for subtype B viruses than for subtype C, while for CD4-IgG2, it was similar for both subtypes, although lower than observed with antibodies. This GRFT-mediated enhancement of HIV-1 binding to b12 was reflected in synergistic neutralization for 2 of the 4 viruses tested. The glycan at position 386, which shields the CD4bs, was involved in both GRFT-mediated enhancement of binding and neutralization synergism between GRFT and b12. Although GRFT enhanced CD4bs exposure, it simultaneously inhibited ligand binding to the coreceptor binding site, suggesting that GRFT-dependent enhancement and neutralization utilize independent mechanisms. This study shows for the first time that GRFT interaction with gp120 exposes the CD4bs through binding the glycan at position 386, which may have implications for how to access this conserved site.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21697467      PMCID: PMC3165825          DOI: 10.1128/JVI.02675-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Authors:  Jose D Murga; Michael Franti; Daniel C Pevear; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

3.  Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

Authors:  Michael B Zwick; Paul W H I Parren; Erica O Saphire; Sarah Church; Meng Wang; Jamie K Scott; Philip E Dawson; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

6.  Glycosylation site-specific analysis of clade C HIV-1 envelope proteins.

Authors:  Eden P Go; Qing Chang; Hua-Xin Liao; Laura L Sutherland; S Munir Alam; Barton F Haynes; Heather Desaire
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

7.  The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.

Authors:  Tonie Cilliers; Jabulani Nhlapo; Mia Coetzer; Dragana Orlovic; Thomas Ketas; William C Olson; John P Moore; Alexandra Trkola; Lynn Morris
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.

Authors:  George Lin; Graham Simmons; Stefan Pöhlmann; Frédéric Baribaud; Houping Ni; George J Leslie; Beth S Haggarty; Paul Bates; Drew Weissman; James A Hoxie; Robert W Doms
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

10.  CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor.

Authors:  Ying Liu; Hao Liu; Byung Oh Kim; Vincent H Gattone; Jinliang Li; Avindra Nath; Janice Blum; Johnny J He
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  29 in total

Review 1.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

2.  The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.

Authors:  Jie Xue; Bart Hoorelbeke; Ioannis Kagiampakis; Borries Demeler; Jan Balzarini; Patricia J Liwang
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

3.  The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin.

Authors:  Jie Xue; Yongguang Gao; Bart Hoorelbeke; Ioannis Kagiampakis; Bo Zhao; Borries Demeler; Jan Balzarini; Patricia J Liwang
Journal:  Mol Pharm       Date:  2012-08-21       Impact factor: 4.939

4.  UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.

Authors:  Hazel T Mufhandu; Elin S Gray; Maphuti C Madiga; Nancy Tumba; Kabamba B Alexandre; Thandeka Khoza; Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris; Makobetsa Khati
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

5.  The High Content of Fructose in Human Semen Competitively Inhibits Broad and Potent Antivirals That Target High-Mannose Glycans.

Authors:  Jacklyn Johnson; Manuel G Flores; John Rosa; Changze Han; Alicia M Salvi; Kris A DeMali; Jennifer R Jagnow; Amy Sparks; Hillel Haim
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

6.  The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells.

Authors:  Kabamba B Alexandre; Elin S Gray; Hazel Mufhandu; James B McMahon; Ereck Chakauya; Barry R O'Keefe; Rachel Chikwamba; Lynn Morris
Journal:  Virology       Date:  2011-12-29       Impact factor: 3.616

7.  Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.

Authors:  Geoffrey Férir; Dana Huskens; Kenneth E Palmer; Daniel M Boudreaux; Michael D Swanson; David M Markovitz; Jan Balzarini; Dominique Schols
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

8.  Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126.

Authors:  Kathryn Fischer; Kimberly Nguyen; Patricia J LiWang
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

9.  Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.

Authors:  Kabamba B Alexandre; Penny L Moore; Molati Nonyane; Elin S Gray; Nthabeleng Ranchobe; Ereck Chakauya; James B McMahon; Barry R O'Keefe; Rachel Chikwamba; Lynn Morris
Journal:  Virology       Date:  2013-08-15       Impact factor: 3.616

10.  Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.

Authors:  Krystal Teasley Hamorsky; Tiffany W Grooms-Williams; Adam S Husk; Lauren J Bennett; Kenneth E Palmer; Nobuyuki Matoba
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.